Veracyte Q4 EPS Beats by 30%, Revenues Rise 18.5% to $140.6M
Veracyte reported adjusted EPS of $0.53 in Q4, 30% above estimates, and revenue of $140.6 million, up 18.5% year-over-year and 1.4% above consensus. Core tests Decipher and Afirma saw double-digit growth, serving over 45,000 patients in the quarter.
1. Q4 Financial Highlights
Veracyte posted adjusted EPS of $0.53 in the fourth quarter, a 30% surprise to consensus, versus $0.36 a year ago. Revenue climbed 18.5% to $140.6 million, surpassing estimates by 1.4% and marking the fourth consecutive quarter of upside.
2. Core Test Growth and Patient Volume
Double-digit growth in the Decipher and Afirma genomic tests drove the revenue increase, with over 45,000 patients served in the quarter, reflecting expanding adoption of Veracyte’s diagnostics portfolio.
3. Outlook and Analyst Estimates
Analysts forecast $0.34 EPS on $131.36 million revenue for Q1 and $1.61 on $577.29 million for the full year; shares have underperformed, down 15.2% YTD, highlighting investor focus on upcoming management commentary.